OPKO Health, Inc. (0KCS.L)
USD 1.63
(0.62%)
USD 1.63
(0.62%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 222.03 Million USD | 5.53% |
| 2022 | 210.4 Million USD | 11.97% |
| 2021 | 187.9 Million USD | -15.36% |
| 2020 | 222 Million USD | 5.11% |
| 2019 | 211.2 Million USD | 568.35% |
| 2018 | 31.6 Million USD | -77.85% |
| 2017 | 142.66 Million USD | 226.46% |
| 2016 | 43.7 Million USD | -11.54% |
| 2015 | 49.4 Million USD | -62.43% |
| 2014 | 131.5 Million USD | -38.89% |
| 2013 | 215.18 Million USD | 4078.29% |
| 2012 | 5.15 Million USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | -100.0% |
| 2009 | 15.34 Million USD | 29.27% |
| 2008 | 11.86 Million USD | 1.52% |
| 2007 | 11.68 Million USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| 2004 | - USD | 0.0% |
| 2003 | - USD | -100.0% |
| 2002 | 108 Thousand USD | -46.53% |
| 2001 | 202 Thousand USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| 1998 | - USD | 0.0% |
| 1997 | - USD | 0.0% |
| 1996 | - USD | 0.0% |
| 1995 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 179.61 Million USD | -45.1% |
| 2024 Q1 | 327.14 Million USD | 47.34% |
| 2023 Q3 | 213.3 Million USD | -15.66% |
| 2023 Q1 | 211.3 Million USD | 0.43% |
| 2023 Q4 | 222.03 Million USD | 4.09% |
| 2023 Q2 | 252.89 Million USD | 19.68% |
| 2023 FY | 222.03 Million USD | 5.53% |
| 2022 Q1 | 247.95 Million USD | 31.96% |
| 2022 Q4 | 210.4 Million USD | 14.26% |
| 2022 FY | 210.4 Million USD | 11.97% |
| 2022 Q3 | 184.14 Million USD | -25.94% |
| 2022 Q2 | 248.62 Million USD | 0.27% |
| 2021 Q1 | 263 Million USD | 18.47% |
| 2021 FY | 187.9 Million USD | -15.36% |
| 2021 Q2 | 220.33 Million USD | -16.23% |
| 2021 Q4 | 187.9 Million USD | -13.72% |
| 2021 Q3 | 217.77 Million USD | -1.16% |
| 2020 Q2 | 303.86 Million USD | 5.21% |
| 2020 Q3 | 253.96 Million USD | -16.42% |
| 2020 Q4 | 222 Million USD | -12.59% |
| 2020 FY | 222 Million USD | 5.11% |
| 2020 Q1 | 288.81 Million USD | 36.75% |
| 2019 Q4 | 211.2 Million USD | -27.44% |
| 2019 Q3 | 291.07 Million USD | -2.03% |
| 2019 Q2 | 297.1 Million USD | 45.85% |
| 2019 FY | 211.2 Million USD | 568.35% |
| 2019 Q1 | 203.7 Million USD | 544.62% |
| 2018 Q3 | 167.95 Million USD | -1.07% |
| 2018 FY | 31.6 Million USD | -77.85% |
| 2018 Q4 | 31.6 Million USD | -81.19% |
| 2018 Q2 | 169.77 Million USD | 99.97% |
| 2018 Q1 | 84.9 Million USD | -40.49% |
| 2017 Q2 | 114.5 Million USD | 29.43% |
| 2017 Q1 | 88.47 Million USD | 102.45% |
| 2017 Q3 | 131.49 Million USD | 14.84% |
| 2017 FY | 142.66 Million USD | 226.46% |
| 2017 Q4 | 142.66 Million USD | 8.49% |
| 2016 Q2 | 93.67 Million USD | -29.66% |
| 2016 FY | 43.7 Million USD | -11.54% |
| 2016 Q3 | 51.5 Million USD | -45.02% |
| 2016 Q4 | 43.7 Million USD | -15.15% |
| 2016 Q1 | 133.17 Million USD | 169.59% |
| 2015 Q2 | 111.35 Million USD | 2.29% |
| 2015 Q1 | 108.85 Million USD | -17.22% |
| 2015 Q3 | 56.06 Million USD | -49.65% |
| 2015 Q4 | 49.4 Million USD | -11.88% |
| 2015 FY | 49.4 Million USD | -62.43% |
| 2014 FY | 131.5 Million USD | -38.89% |
| 2014 Q1 | 227.9 Million USD | 5.91% |
| 2014 Q2 | 119.31 Million USD | -47.65% |
| 2014 Q4 | 131.5 Million USD | 11.91% |
| 2014 Q3 | 117.51 Million USD | -1.51% |
| 2013 FY | 215.18 Million USD | 4078.29% |
| 2013 Q2 | 192.16 Million USD | -3.98% |
| 2013 Q1 | 200.12 Million USD | 3785.96% |
| 2013 Q3 | 212.26 Million USD | 10.46% |
| 2013 Q4 | 215.18 Million USD | 1.37% |
| 2012 Q3 | 3.95 Million USD | -83.79% |
| 2012 Q1 | - USD | 0.0% |
| 2012 FY | 5.15 Million USD | 0.0% |
| 2012 Q2 | 24.38 Million USD | 0.0% |
| 2012 Q4 | 5.15 Million USD | 30.25% |
| 2011 FY | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q1 | - USD | -100.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 FY | - USD | -100.0% |
| 2009 Q2 | 14.49 Million USD | 2.87% |
| 2009 Q3 | 14.91 Million USD | 2.88% |
| 2009 Q4 | 15.34 Million USD | 2.88% |
| 2009 FY | 15.34 Million USD | 29.27% |
| 2009 Q1 | 14.08 Million USD | 18.72% |
| 2008 Q1 | 13.42 Million USD | 14.82% |
| 2008 Q2 | 11.78 Million USD | -12.18% |
| 2008 Q4 | 11.86 Million USD | 0.25% |
| 2008 FY | 11.86 Million USD | 1.52% |
| 2008 Q3 | 11.83 Million USD | 0.43% |
| 2007 Q1 | 4.81 Million USD | 0.0% |
| 2007 Q4 | 11.68 Million USD | 53.04% |
| 2007 FY | 11.68 Million USD | 0.0% |
| 2007 Q3 | 7.63 Million USD | 94.45% |
| 2007 Q2 | 3.92 Million USD | -18.35% |
| 2006 Q4 | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2005 Q1 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| 2005 Q4 | - USD | 0.0% |
| 2005 Q3 | - USD | 0.0% |
| 2005 Q2 | - USD | 0.0% |
| 2004 Q1 | - USD | 0.0% |
| 2004 Q2 | - USD | 0.0% |
| 2004 Q4 | - USD | 0.0% |
| 2004 FY | - USD | 0.0% |
| 2004 Q3 | - USD | 0.0% |
| 2003 FY | - USD | -100.0% |
| 2003 Q3 | 34 Thousand USD | -42.37% |
| 2003 Q1 | 84 Thousand USD | -22.22% |
| 2003 Q4 | - USD | -100.0% |
| 2003 Q2 | 59 Thousand USD | -29.76% |
| 2002 Q4 | 108 Thousand USD | 36.71% |
| 2002 FY | 108 Thousand USD | -46.53% |
| 2002 Q1 | 202 Thousand USD | 0.0% |
| 2002 Q2 | 148 Thousand USD | -26.73% |
| 2002 Q3 | 79 Thousand USD | -46.62% |
| 2001 FY | 202 Thousand USD | 0.0% |
| 2001 Q4 | 202 Thousand USD | 0.0% |
| 2001 Q3 | - USD | -100.0% |
| 2001 Q2 | 687 Thousand USD | -8.4% |
| 2001 Q1 | 750 Thousand USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 1999 Q2 | - USD | -100.0% |
| 1999 Q4 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1999 Q1 | 1 Million USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1998 Q4 | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| 1998 Q1 | - USD | 0.0% |
| 1998 Q2 | - USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| 1997 Q2 | - USD | 0.0% |
| 1997 Q1 | - USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| 1997 Q4 | - USD | 0.0% |
| 1996 Q3 | - USD | 0.0% |
| 1996 Q4 | - USD | 0.0% |
| 1996 Q2 | - USD | 0.0% |
| 1996 Q1 | - USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| 1995 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | 24.37 Million USD | -811.021% |
| Dynavax Technologies Corporation | 252.41 Million USD | 12.037% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -568.858% |
| Perrigo Company plc | 3.63 Billion USD | 93.888% |
| Illumina, Inc. | 1.48 Billion USD | 85.088% |
| Thermo Fisher Scientific Inc. | 31.3 Billion USD | 99.291% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -22103.4% |
| Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 97.24% |
| IQVIA Holdings Inc. | 12.95 Billion USD | 98.286% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -27.787% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 91.785% |
| Unity Biotechnology, Inc. | 23.53 Million USD | -843.26% |
| Waters Corporation | 2.3 Billion USD | 90.369% |
| Biogen Inc. | 7.18 Billion USD | 96.911% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | -562.491% |
| Evolus, Inc. | 120.35 Million USD | -84.476% |
| Adicet Bio, Inc. | 17.7 Million USD | -1154.217% |
| Cara Therapeutics, Inc. | 37.07 Million USD | -498.813% |
| bluebird bio, Inc. | 224.41 Million USD | 1.063% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 55.73% |
| FibroGen, Inc. | 89.69 Million USD | -147.538% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 91.882% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -6755.798% |
| Homology Medicines, Inc. | 43.17 Million USD | -414.253% |
| Geron Corporation | 35.05 Million USD | -533.46% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 90.524% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | 42.754% |
| Myriad Genetics, Inc. | 130.9 Million USD | -69.621% |
| Viking Therapeutics, Inc. | 936 Thousand USD | -23621.581% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | -129.5% |
| Zoetis Inc. | 6.56 Billion USD | 96.617% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -4943.935% |
| Mettler-Toledo International Inc. | 1.97 Billion USD | 88.761% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | 62.564% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | 69.362% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -549.412% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | 84.145% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | -385.926% |
| Verastem, Inc. | 40.08 Million USD | -453.894% |
| Nektar Therapeutics | 112.62 Million USD | -97.145% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | -24.689% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -7122.967% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | 80.395% |
| Exelixis, Inc. | 189.94 Million USD | -16.894% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 14.04% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 130.06 Million USD | -70.71% |
| Imunon, Inc. | 1.13 Million USD | -19388.753% |
| Blueprint Medicines Corporation | 610.96 Million USD | 63.658% |
| Insmed Incorporated | 1.19 Billion USD | 81.394% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 85.19% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -289.615% |
| TG Therapeutics, Inc. | 100.11 Million USD | -121.772% |
| Incyte Corporation | 29.16 Million USD | -661.381% |
| Emergent BioSolutions Inc. | 446.5 Million USD | 50.272% |